Related Experiment Video
Updated: Aug 17, 2025
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
12.9K
Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma
Chenglong Chen1,2, Qianyu Shi2,3, Jiuhui Xu2,3
1Department of Orthopedics, Beijing Jishuitan Hospital, Beijing, People's Republic of China.
Cell Death Discovery
|December 12, 2022
Summary
Tyrosine kinase inhibitors (TKIs) show promise in treating osteosarcoma (OS) by improving progression-free survival. However, acquired drug resistance remains a significant challenge, necessitating further research into overcoming this limitation for better patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Biomedical Research
Background:
- Osteosarcoma (OS) is the most common primary malignant bone tumor.
- While survival rates improved with chemotherapy and resection, progress has stagnated.
- Tyrosine kinase inhibitors (TKIs) offer potential but face challenges in advanced OS.
Purpose of the Study:
- To review the applications of TKIs in osteosarcoma.
- To elucidate the mechanisms of TKI resistance in OS.
- To explore strategies for overcoming TKI resistance in OS treatment.
Main Methods:
- Literature review of TKI applications in OS.
- Analysis of TKI resistance mechanisms.
- Examination of strategies to overcome TKI resistance.
- Inclusion of data from animal, cell models, clinical trials, and bioinformatics.
Main Results:
- TKIs improve progression-free survival in advanced OS but not overall survival.
- Acquired drug resistance is a primary reason for unchanged overall survival.
- Understanding TKI resistance mechanisms and solutions is crucial but limited.
Conclusions:
- TKIs represent a novel therapeutic avenue for osteosarcoma.
- Addressing TKI resistance is critical for improving patient outcomes.
- Further research integrating preclinical and clinical data is needed.
Related Concept Videos
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
01:26Receptor Tyrosine Kinases
13.5K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.5K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.6K